Clinical Trials on Sporadic Inclusion Body Myositis in Denmark

Total 3 results

University of Southern Denmark
Odense University Hospital

Completed

Blood-flow Restricted Exercise in Inclusion Body Myositis

Sporadic Inclusion Body Myositis

Denmark
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients (RESILIENT)

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Novartis Pharmaceuticals

Completed

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan

3

Subscribe